In the present study, the determinants of fasting plasma homocysteine in diabetic subjects were examined; whether plasma homocysteine and vascular disease are related and the influence of the C677T polymorphism in the methylenetetrahydrofolate reductase (MTHFR) gene on serum and erythrocyte folate, plasma homocysteine and vascular disease. Diabetic clinic subjects (Type I, n l 354; Type II, n l 392) were recalled for a cross-sectional survey. Standard methods were used to measure biochemical variables and to characterize vascular disease and MTHFR genotype. Plasma homocysteine was significantly and directly related to age, male sex and serum urea, and inversely related to serum folate and vitamin B12, independently in stepwise regression. When corrected for age and sex, homocysteine was significantly related to hard end points of coronary artery disease and stroke (each P 0.01), remaining significant when additionally adjusted for serum folate (P l 0.043 and P l 0.019 respectively). Serum folate was not clearly related to these events, although there was a trend to associate with the lower quintile of serum folate. The MTHFR genotype was not a determinant of plasma homocysteine, even in those in the lowest quintile of serum folate, nor of vascular disease. TT homozygosity at residue 677 was associated with elevation of total erythrocyte folate compared with both other genotypes (P 0.0001), almost certainly due to the diversion of 5,10-methylenetetrahydrofolate into derivates subsequent to the partial metabolic block that results from the MTHFR enzyme defect. In conclusion, in this clinic cohort of people with diabetes, vascular disease is related to plasma homocysteine, which is correlated with serum folate. The MTHFR genotype does not significantly influence either plasma homocysteine or vascular disease, despite it being a determinant of erythrocyte folate, which reflects its effect on folate metabolism.
INTRODUCTION
Diabetes mellitus is a common cause of cardiovascular disease and it is important to identify novel risk factors that might amplify the risk associated with the diabetic Key words : diabetes, folate, homocysteine, methylenetetrahydrofolate, vascular disease.
Abbreviations : CAD, coronary artery disease ; CI, confidence interval ; CV, coefficient of variation ; CVA, cerebrovascular accident ; MTHFR, methylenetetrahydrofolate reductase ; OR, odds ratio.
Correspondence : Professor Frank M. van Bockxmeer (e-mail Frank.VB!health.wa.gov.au) state. There is now abundant evidence (reviewed in [1] [2] [3] [4] [5] [6] ) that the level of plasma homocysteine is related to vascular disease and considerable evidence that this is an aetiological relationship. In diabetic, as in non-diabetic, subjects fasting plasma homocysteine has been inversely related to folate and vitamin B12 levels [7] [8] [9] and to renal function or albuminuria [7, 8, 10] , and has been related to macrovascular complications [7, 9, 10] and death from cardiovascular disease [11] [12] [13] .
In contrast to the above substantial evidence, the C677T polymorphism of the gene for methylenetetrahydrofolate reductase (MTHFR), the enzyme involved in the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which re-methylates homocysteine to methionine [14] , has not been closely studied in a diabetic population. The T allele produces a thermolabile variant enzyme with reduced activity [14] , so that TT homozygosity can result in elevation of plasma homocysteine [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] , especially in the presence of low serum folate [15] [16] [17] . Homozygosity occurs within a range of 5-21 % in different populations, approx. 10-11 % in a local normal population we have studied previously [25] . Despite some studies indicating that TT homozygosity might produce a predisposition to vascular disease (reviewed in [4, 19] ), a meta-analysis of the numerous studies to 1998 [20] concluded that it is not an important determinant, at least in well-nourished populations, a negative conclusion that has been generally supported subsequently [21] [22] [23] [24] . The relevance of the polymorphism to hyperhomocysteinaemia and to vascular disease in the diabetic state has not been adequately studied. The aims of the present study were, therefore, to document the relationships between the C677T gene polymorphism, plasma homocysteine and overt macrovascular disease in a large number of diabetic subjects, taking account of other variables related to plasma homocysteine, including folate, vitamin B12, pyridoxine and renal function. Since the polymorphism alters the cellular metabolism of folate, and there is divergence in the literature concerning its effect on erythrocyte folate levels [16, [26] [27] [28] , the opportunity was also taken to measure total folate in erythrocytes.
METHODS

Patients and definitions
Data were collected on one occasion from patients attending the Royal Perth Hospital Diabetic Clinic for survey purposes during a 2-year period from mid 1996 to mid 1998. Patients (n l 746) with Type I (n l 354) or Type II (n l 392) diabetes, approximately half of the total clinic population, who gave written informed consent for the collection, storage and analysis of blood samples and DNA with the approval of the hospital Ethics Committee and in accord with the Declaration of Helsinki (1989) , are reported in this study. Diabetes was classified as Type I on clinical criteria : diagnosis before the age of 40 years, and the permanent need for insulin within 2 years. In addition, 47 of the Type II subjects were receiving insulin at the time of cross-sectional documentation. The patients ' age was 57.6p0.5 years (49.8p0.8 years and 64.7p0.5 years for Type I and Type II respectively), and 430 were male. Except where stated, the results of the Type I and Type II subjects are considered collectively.
Hard end points for the presence of coronary artery disease (CAD) were defined as previous welldocumented acute myocardial infarction, coronary artery bypass surgery or coronary angioplasty. Total clinical CAD was also documented at the Diabetic Clinic review by the addition of those with resting ECG Q-wave criteria according to Minnesota coding [29] or a clinical history of angina pectoris. A history of documented stroke defined cerebrovascular accident (CVA).
Biochemical methods
Blood from fasting subjects was obtained for serum, plasma (plus 1.8 mg\ml EDTA) and erythrocytes. Plasma for homocysteine was separated as soon as possible and within 1 h. Plasma homocysteine was measured by fluorescence polarization immunoassay on an IMx analyser (Abbott Laboratories, Abbott Park, IL, U.S.A.) [30] . The inter-assay coefficient of variation (CV) of this measurement was 5 %. Serum and erythrocyte folate (using blood with EDTA) were measured by ion-capture enzyme immunoassay on an AxSYM analyser (Abbott Laboratories) [31] ; erythrocyte folate after lysis with ascorbic acid and guanidine hydrochloride, and serum vitamin B12 by microparticle enzyme immunoassay. The CV for folate measurement was 8 %. Serum pyridoxal 5-phosphate was measured by microbiological assay using Lactobacillus casei (A.T.C.C. 7469) [32] . Serum urea was measured using the urease method on a Hitachi 917 analyser (Boehringer Mannheim, Mannheim, Germany).
The C677T polymorphism in the MTHFR gene was characterized by PCR and HinfI restriction enzyme digestion as described by Frosst et al. [14] , followed by PAGE as described previously [25] .
Statistical methods
Associations between continuous and categorical variables were examined using ANOVA and associations between categorical variables using χ# tests. Bonferroni adjustment was applied to the multiple comparisons following ANOVA. Binary logistic regression was used to determine associations between end points for cardiovascular disease and independent variables, with and without adjustment for age, sex and other variables as described. Associations between plasma homocysteine and other variables were examined in unvariate regression. Significant predictors of homocysteine were then used in stepwise regression with criteria of P 0.05 for entry and P 0.1 for exit. This method was used to identify the best predictor among a set of correlated variables, for example avoiding entry of both serum and erythrocyte folate into the model. All analyses were carried out using SPSS 10.0 (SPSS, Chicago, IL, U.S.A.). P 0.05 was considered statistically significant. Results are expressed as the meanspS.E.M.
RESULTS
Of the 746 subjects, 117 (16 %) had a plasma homocysteine level 14 µmol\litre, a level often regarded as high [13, 33] . Fasting plasma homocysteine levels were significantly related to the variables in Table 1 , which shows univariate regression coefficients and the results of stepwise regression. In univariate analysis, plasma homocysteine was directly related to age, male gender and plasma urea, and was inversely related to serum folate, vitamin B12 and to the pyridoxal 5h-phosphate level, but was not significantly related to erythrocyte folate. In stepwise regression, each of age, sex, urea, serum folate and B12 was independently significant (Table 1) , but pyridoxal was not. The model containing the significant variables explained 46 % of the variance in plasma homocysteine. Correlations of homocysteine with serum folate were essentially the same in those with Type I and Type II diabetes (linear regression, r lk0.277, P 0.001, and r lk0.273, P 0.001 respectively). Plasma homocysteine was significantly different between quintiles of serum folate (P 0.001, ANOVA ; Table 2 ), but it was only in the lowest quintile of folate ( 15 nmol\litre) that homocysteine (13.4p0.5 µmol\ litre) was significantly higher than in the other four quintiles (all P 0.001), whereas the levels were not different in those other quintiles ( Table 2) . The difference in homo- cysteine between quantities of serum folate was apparent in both Type I and Type II subjects examined separately (each P 0.001, ANOVA), the difference residing in the lower quintile. Plasma homocysteine also differed between quintiles of erythrocyte folate (P 0.001), being significantly higher in the lowest quintile compared with each of the others (P 0.001, Table 2 ). Plasma homocysteine was not significantly dependent upon MTHFR genotype either in the whole group of patients (Table 3) , in subgroups divided at the median serum folate (21.3 nmol\litre), nor in any quintile of serum folate. That is, even in the lowest quintile of serum folate, in which it might have been expected from previous studies that plasma homocysteine would be higher in those homozygous for the T allele, plasma homocysteine was 14.3p1.5 µmol\litre (n l 11) in TT, 14.0p0.8 µmol\litre (n l 67) in CT and 12.8p0.6 µmol\litre (n l 72) in CC (not significant). The relatively small number of TT subjects with low serum folate should, however, be noted.
The hard end points of CAD were significantly related to the homocysteine level, which was 12.8p 0.5 µmol\litre in the 101 subjects with CAD and 9.9p0.2 µmol\litre in the 645 subjects without (P 0.0001). The levels were similar with the same significance when those with clinical angina and ECG criteria alone were included. The 40 subjects with a previous CVA had a higher plasma homocysteine compared with those who did not (13.8p0.9 µmol\litre compared with 10.1p0.2 µmol\litre; P 0.001). In multivariate analysis adjusting for age and sex, homocysteine remained significantly related to CAD and CVA (each P 0.01) and the relationships remained significant adjusting for the type of diabetes. With additional adjustment for serum folate, plasma homocysteine remained significantly related to CAD [odds ratio (OR), 1.04; 95 % confidence interval (CI), 1.01-1.09, P l 0.043] and CVA (OR, 1.07; CI, 1.01-1.12, P l 0.019). However, urea was higher in those with vascular disease (CAD versus no CAD : 8.6p0.6 mmol\litre versus 7.0p 0.1 mmol\litre, P 0.001) and, with further adjustment for urea, significance for each was lost (CAD : OR, 1.02; CI, 0.97-1.08, P l 0.397 ; CVA : OR, 1.05; CI, 0.99-1.12, P l 0.114).
Serum folate, either uncorrected or adjusted for age and sex, was not significantly related to any of the cardiovascular end points (ANOVA). The question was also examined according to quintiles of serum folate. Although relationships were not significant, there was a trend for cardiovascular disease to aggregate within the lower quintile of both serum and erythrocyte folate. For example, 20 % of those in the lowest quintile of serum folate had CAD compared with 12 % in the other quintiles, 30 % of those with CAD being in the lowest quintile (χ#, 4 degrees of freedom, P l 0.071). Pyridoxal was not associated with cardiovascular disease, either uncorrected or adjusted for age and sex or, additionally, for homocysteine. The vascular end points were not related to the MTHFR genotype.
Erythrocyte and serum folates were significantly dependent upon MTHFR genotype (P 0.0001 and P l 0.027 respectively, Table 3 ). Serum folate was only marginally higher in TT homozygotes than in those with the CT genotype (P l 0.036) and was not significantly higher than in the CC genotype (Table 3) . Although erythrocyte folate correlated with serum folate in both Type I and Type II diabetes (each P 0.0001) and in each of the three MTHFR genotypes (P 0.0001), erythrocyte folate was the more strikingly and significantly dependent upon MTHFR genotype (P 0.0001; Table 3 ). TT homozygotes had a much higher erythrocyte folate compared with the CT or CC genotypes, which were similar [1167p47 nmol\litre (n l 88) versus 763p17 nmol\litre (n l 292) and 775p15 nmol\litre (n l 366) respectively]. Examination of quintiles of erythrocyte folate substantiated a significant effect 
DISCUSSION
The results of the present study, showing the effect of MTHFR genotype on erythrocyte folate and a smaller effect on serum folate, but lack of its influence on plasma homocysteine or vascular disease in the diabetic subjects, are novel, but the more frequently studied aspects need to be discussed in the context of current knowledge. The present study found the vascular disease end points of CAD and stroke to be significantly related to plasma homocysteine. It confirms the associations with vascular complications found by Hofmann et al. [10] in 75 subjects with Type I diabetes, and by Lanfredini et al. [7] in 33 and Smulders et al. [9] in 85 Type II diabetic subjects. Additionally, recent prospective studies [11] [12] [13] of diabetic subjects have found cardiovascular mortality to be related to fasting plasma homocysteine. However, Stabler et al. [8] studied 452 Type II diabetic subjects and did not find plasma homocysteine to be related to macrovascular disease, either CAD or CVA.
As seen in many studies, including several in diabetic subjects [7] [8] [9] , plasma homocysteine was inversely related to serum folate, but a significantly higher homocysteine level was seen only in those in the lowest quintile of serum folate. Significantly higher plasma homocysteine was also found in the lowest quintile of erythrocyte folate, which is consistent with other observations [34] and with erythrocyte folate reflecting folate stores, despite our novel observation concerning the influence of the MTHFR polymorphism on erythrocyte folate. That 15 nmol\litre was the cut-off point for the lowest quintile of serum folate indicates that our subjects were relatively replete in folate, only 31 (4 %) having a folate level 9.2 nmol\litre, a point below which homocysteine was found in the Framingham study [33] to be particularly raised. The level at which homocysteine is considered raised and deleterious, if indeed there is a causeeffect relationship with vascular disease, is also arbitrary, but it has been taken to be around 14 µmol\litre [13, 33] . It might be noted that even in those with vascular disease in our present study, the mean homocysteine was just below this level and only 16 % had a plasma homocysteine above 14 µmol\ litre.
The relationships between homocysteine and cardiovascular end-points were retained when adjusted, not only for age and sex, but also for serum folate. This was despite the relationship between serum folate and homocysteine, which might have been expected to destroy the independence of homocysteine. Folate itself was not clearly related to cardiovascular end-points. These facts suggest that homocysteine was more specifically related to end points than folate, as concluded by others [34] . Whereas pyridoxal 5h-phosphate correlated with fasting plasma homocysteine in univariate analysis, it was not a significant independent determinant. It was not related to vascular events, in contrast with the findings of studies [21, 34] that have suggested it to predict vascular disease independent of homocysteine.
It was not an aim of this study to compare diabetic with non-diabetic subjects, nor to examine a comprehensive range of vascular risk factors. In a previous prospective study of Type II diabetic subjects attending this diabetic clinic from 1986 to 1993 [35] , death from all cardiovascular disease was significantly related to diastolic blood pressure, high-density lipoprotein cholesterol, glycated haemoglobin and microalbuminuria, whereas total cholesterol, log triacylglycerol and systolic blood pressure were additionally related to coronary heart disease mortality.
There has recently been considerable interest in the C677T polymorphism of the MTHFR gene, but little study of this in diabetic subjects. There is agreement that TT homozygosity, inducing a thermolabile variant of the enzyme with reduced activity [14] , is generally a factor in raising plasma homocysteine when serum folate is low [15, 17] . Yet, even in those in the lower quintile of serum folate, we found no elevation of plasma homocysteine in these diabetic subjects. This could be due partly to their relative folate sufficiency, perhaps to the dietary management of a clinic-attending diabetic group. At least it indicates that the MTHFR polymorphism is not an important determinant of plasma homocysteine in such a population. Consistent with this, the polymorphism was not significantly related to vascular disease, in agreement with most studies, even when they have found it to influence plasma homocysteine. Since the meta-analyses in 1998 with these conclusions [20] , studies reporting a significant effect on homocysteine, but not on vascular disease, have included those on ischaemic stroke [23] , 3-year mortality in patients with angiographic CAD [24] , and in a mixed group with arterial or venous thrombosis [22] .
The relationship between the MTHFR polymorphism and folate, but especially erythrocyte folate, is interesting in view of the divergence in the literature. Molloy et al. [26] and Zittoun et al. [27] found TT homozygosity to be associated with a decrease in erythrocyte folate, whereas van der Put et al. [16] reported an increase, as we found in the present study. The former two studies [26, 27] carried out a microbiological method utilizing Lactobacillus casei, whereas the present study and the latter study [16] used radioimmunoassay techniques. Reconciling these results, Molloy et al. [36] found a difference between these techniques in the measurement of whole blood folate; in TT homozygotes, radioassay gave a higher level than did the microbiological method, whereas in the other genotypes it measured a lower folate. The findings of Bagley and Selhub [28] help to explain this phenomenon by using column-separation and a chromatographic technique to separate folate metabolites. They found [28] , as expected from decreased MTHFR enzyme activity, that TT homozygote erythrocytes contained significantly less methyl folate than cells from CC individuals, whereas there was an accumulation of formylated folate not present in the latter. That is, the partial reductase metabolic block produced by TT homozygosity allows the diversion of 5,10-methylenetetrahydrofolate to formylated products, resulting in their accumulation. Although the method of erythrocyte lysis may be critical to the absolute levels of erythrocyte folate measured [37] , this is unlikely to be relevant to our findings. Nor are our results specific to the diabetic state, as indicated by the results of others [16, 23] who used similar methods.
In conclusion, we have confirmed that plasma homocysteine in diabetic subjects is independently related to age, sex, serum folate, vitamin B12 and renal function. Although plasma homocysteine was elevated in those with the lowest serum and erythrocyte folate, it was not elevated in those homozygous for the T allele of MTHFR, even in the low folate group. Coronary and cerebrovascular disease were related to the plasma homocysteine level, but not to the MTHFR genotype. Despite the genotype having metabolic effects expressed as an influence on serum, and especially erythrocyte, folate levels, it cannot be considered an important determinant of vascular disease in a well-nourished diabetic clinic population.
